Difference between revisions of "Merck Sharp & Dohme LLC patent applications published on July 25th, 2024"

From WikiPatents
Jump to navigation Jump to search
(Creating a new page)
Line 1: Line 1:
−
'''Summary of the patent applications from Merck Sharp & Dohme LLC on July 25th, 2024'''
 
−
 
−
1. **Summary**:
 
−
The recent patents filed by Merck Sharp & Dohme LLC introduce innovative technologies in the fields of enzyme engineering, cancer treatment, monoclonal antibodies, and chemical synthesis. These patents focus on enhancing transaminase enzymes for specific compound reduction, utilizing PD-1 receptor antagonists for personalized cancer therapy, developing monoclonal antibodies for RSV infections, and inhibiting the G12C mutant of the KRAS protein for cancer treatment. The organization's patents showcase advancements in biotechnology, pharmaceuticals, and precision medicine.
 
−
 
−
2. **Key Points of Patents**:
 
−
  * Transaminase enzymes with improved properties for reducing specific compounds.
 
−
  * PD-1 receptor antagonists for personalized cancer therapy based on biomarker alterations.
 
−
  * Monoclonal antibodies with high anti-RSV neutralizing titers for RSV infections.
 
−
  * Compounds inhibiting the G12C mutant of the KRAS protein for cancer treatment.
 
−
 
−
3. **Notable Applications**:
 
−
  * Pharmaceutical industry for drug synthesis, chemical industry for manufacturing processes, and biotechnology for enzyme engineering.
 
−
  * Personalized cancer treatment based on biomarker activity, targeted therapy for genetic alterations, and advancements in precision medicine for cancer care.
 
−
  * Treatment of RSV infections, prevention in high-risk populations, and development of new immunotherapy agents.
 
−
  * Potential for improved outcomes in cancer patients, enhanced protection in vulnerable populations, and new therapeutic interventions.
 
−
 
−
 
−
 
−
 
 
==Patent applications for Merck Sharp & Dohme LLC on July 25th, 2024==
 
==Patent applications for Merck Sharp & Dohme LLC on July 25th, 2024==
  

Revision as of 07:48, 26 July 2024

Patent applications for Merck Sharp & Dohme LLC on July 25th, 2024

ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS (18557667)

Main Inventor

Ashok Arasappan


IL4I1 INHIBITORS AND METHODS OF USE (18556196)

Main Inventor

George Madalin GIAMBASU


SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT (18557458)

Main Inventor

Kazuaki SHIBATA


ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS (18630437)

Main Inventor

Kalpit A. Vora


METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST (18561331)

Main Inventor

Razvan CRISTESCU


TRANSAMINASE ENZYMES FOR THE TRANSAMINATION OF (1S,5R)-6,8-DIOXABICYCLO[3.2.1]OCTAN-4-ONE ([[Merck Sharp & Dohme LLC (18563157). TRANSAMINASE ENZYMES FOR THE TRANSAMINATION OF (1S,5R)-6,8-DIOXABICYCLO[3.2.1]OCTAN-4-ONE simplified abstract|18563157]])

Main Inventor

Karla M. Camacho Soto

Retrieved from "http://wikipatents.org/index.php?title=Merck_Sharp_%26_Dohme_LLC_patent_applications_published_on_July_25th,_2024&oldid=207415"